Trades of Eli Lilly shares were made on Trump’s behalf as drugmaker benefitted from his policies
Summary
Financial disclosures show that trades worth hundreds of thousands of dollars were made in Eli Lilly shares on behalf of President Donald Trump in early 2026. During this time, the Trump administration introduced policies that helped expand access to Eli Lilly’s weight-loss drugs.Key Facts
- Trades in Eli Lilly shares worth up to $680,000 were made between January and March 2026 on President Trump’s behalf.
- The disclosures reveal thousands of stock and bond trades linked to Trump valued between $220 million and $750 million.
- Eli Lilly benefited from Trump administration actions, including expanding Medicare coverage for its weight-loss drugs called GLP-1 medications.
- The government launched TrumpRx, a website to lower prescription drug costs that initially featured Eli Lilly’s medications.
- The Trump Organization said President Trump does not pick or approve any of the investments; professional firms manage the trading.
- The filings show much more trading activity than was reported in Trump’s first year during his second term.
- President Trump has strong ties with major US companies and recently took CEOs from some to a state visit in China.
- Critics note that President Trump’s and his family’s growing wealth draws attention amid ongoing financial challenges for many Americans.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.